NCT01019824View on ClinicalTrials.gov

Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

411

Participants

Timeline

Start Date

March 20, 2009

Primary Completion Date

May 11, 2010

Study Completion Date

August 9, 2011

Conditions
Pain
Interventions
DRUG

Ralfinamide

Ralfinamide Oral Tablets, 160 or 320 mg per day

Trial Locations (1)

Unknown

Parexel, London

Sponsors

Collaborators (2)

Parexel
CliniRx
All Listed Sponsors
collaborator

Parexel

INDUSTRY

collaborator

CliniRx

UNKNOWN

lead

Newron Pharmaceuticals SPA

INDUSTRY